고인산혈증 치료제 시장 : 약제 유형별, 용도별, 유통 채널별, 지역별

Hyperphosphatemia Drugs Market is estimated to be valued at USD 3.94 billion in 2026 and is expected to reach USD 7.39 billion by 2033, growing at a compound annual growth rate (CAGR) of 9.4% from 2026 to 2033.

The global hyperphosphatemia drugs market comprises drug type categories such as Calcium-Based Phosphate Binders, Non-Calcium-Based Phosphate Binders, and Iron-Based Phosphate Binders, serving applications including Dialysis Patients, Non-Dialysis Chronic Kidney Disease (CKD) Patients, and Pediatric Patients. These offerings are adopted across Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies and other areas, where they support improved efficiency, performance, and reliability. Growing adoption across these segments, combined with ongoing product innovation, continues to support expansion of the market.

Market Dynamics:

Rising demand across key application areas, increasing emphasis on efficiency and performance, and continued product innovation are major factors expected to drive growth of the global hyperphosphatemia drugs market. Expanding adoption among Hospital Pharmacies, and Retail Pharmacies and growing investment in advanced solutions are further supporting market expansion.

For instance, providers are increasingly developing offerings tailored to Dialysis Patients and related applications. Moreover, ongoing research and development, along with the integration of new technologies, is expected to create new growth opportunities for market players over the forecast period.

Key features of the study:

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global hyperphosphatemia drugs market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Amgen Inc., Shire Pharmaceuticals, Vifor Pharma, Akebia Therapeutics, Kyowa Kirin Co. Ltd., Nipro Corporation, Baxter International Inc., Taiho Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, and Otsuka Holdings Co, Ltd, among others.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global hyperphosphatemia drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hyperphosphatemia drugs market.

Detailed Segmentation:

• Global Hyperphosphatemia Drugs Market, By Drug Type (Revenue, USD Bn, 2021 - 2033)
• Calcium-Based Phosphate Binders
• Non-Calcium-Based Phosphate Binders
• Iron-Based Phosphate Binders
• Others
• Global Hyperphosphatemia Drugs Market, By Application (Revenue, USD Bn, 2021 - 2033)
• Dialysis Patients
• Non-Dialysis Chronic Kidney Disease (CKD) Patients
• Pediatric Patients
• Others
• Global Hyperphosphatemia Drugs Market, By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others
• Regional Insights (Revenue, USD Bn, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa
• Company Profiles:
• Amgen Inc.*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
• Shire Pharmaceuticals
• Vifor Pharma
• Akebia Therapeutics
• Kyowa Kirin Co. Ltd.
• Nipro Corporation
• Baxter International Inc.
• Taiho Pharmaceutical Co. Ltd.
• Takeda Pharmaceutical Company Limited
• Otsuka Holdings Co, Ltd

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Preview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Application
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Recent Product Launches
• Epidemiology
• Merger, Acquisition, and Collaboration
• Regulatory Scenario
• Key Developments
• PEST Analysis
• Partnership Scenario
• Brand and Pricing Analysis
• Distributors Landscape
• Porters Analysis
• Technological Advancements
• Key Developments
• Market Trend
• Future Prospective
• Top Market Players by Revenue

4. Hyperphosphatemia Drugs Market By Drug Class, 2026-2033, (US$ Billion)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022-2033
  • Segment Trends
• Calcium-Based Phosphate Binders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
• Non-Calcium-Based Phosphate Binders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
• Iron-Based Phosphate Binders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)

5. Hyperphosphatemia Drugs Market By Application, 2026 - 2033, (US$ Billion)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022-2033
  • Segment Trends
• Dialysis Patients
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
• Non-Dialysis Chronic Kidney Disease (CKD) Patients
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
• Pediatric Patients
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)

6. Hyperphosphatemia Drugs Market By Distribution Channel, 2026 - 2033, (US$ Billion)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022-2033
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)

7. Hyperphosphatemia Drugs Market By Region, 2026 - 2033, (US$ Billion)

• Introduction
  • Market Share Analysis, By Region, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, For Regions, 2022-2033
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Benelux
    • Denmark
    • Norway
    • Sweden
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
    • China
    • Taiwan
    • India
    • Japan
    • Indonesia
    • Malaysia
    • Philippines
    • Singapore
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East & Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
• Bahrain
• Kuwait
• Oman
• Qatar
• Saudi Arabia
• UAE
• Israel
• South Africa
• North Africa
• Central Africa
• Rest of the Middle East

1. Competitive Landscape

• Amgen Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Shire Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Vifor Pharma
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Akebia Therapeutics
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Kyowa Kirin Co. Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Nipro Corporation
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Baxter International Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Taiho Pharmaceutical Co. Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Takeda Pharmaceutical Company Limited
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Otsuka Holdings Co., Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

2. Section

• Research Methodology
• About Us